CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT01444417
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:36:18.160308+00:00
- Published At
- 2017-01-19T00:00:00+00:00
- Record Updated At
- 2017-02-09
- Results Posted At
- 2017-01-19
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Idiopathic Thrombocytopenic Purpura", "Thrombocytopenia", "Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)", "Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)", "Thrombocytopenic Purpura", "Immune Thrombocytopenia"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-02-09"- protocolSection.identificationModule.nctId
"NCT01444417"- protocolSection.identificationModule.officialTitle
"A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE3"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2017-01-19"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.